Factory Capital Commits $25M+ to Build Women's Midlife Health Into an Institutional VC Category
TL;DR
Sydney-based Factory Capital has unveiled plans to invest upwards of $25 million to build out women's midlife health as an institutional investment category. The strategy starts with the Institute Advancing Women's Health (InAWH), a new Austin-based non-profit chaired around clinical infrastructure, before backing five to ten commercial businesses that can scale on top of that foundation. Partner and Managing Director Anna Samuelsson is positioning Factory Capital as a category creator in a $490 billion peri- and post-menopause market that almost no institutional capital has touched.
Key Takeaways
This is category creation, not a vanilla thematic fund. Most VC managers chasing women's health write cheques into individual startups and hope the surrounding infrastructure catches up. Factory Capital is doing the opposite. It is building the clinical infrastructure (protocols, care pathways, clinician training) through a non-profit before backing the businesses that monetise on top, a structural play more reminiscent of how the US oncology venture ecosystem matured in the 2000s.
The Austin-based non-profit anchor is a deliberate market-making lever. By housing the Institute Advancing Women's Health in the US rather than Australia, Factory Capital gives itself proximity to the world's largest pharmaceutical and digital health markets, plus a credible academic-clinical conversation partner. Paula Schneider, who previously turned around The Wendy Williams Show parent and ran The Susan G. Komen Foundation, has been named CEO of InAWH.
$490 billion is the headline market, but the investable wedge is the unbundling of menopause care. Most of the published menopause TAMs aggregate HRT, supplements, telehealth, B2B benefits and devices into one number. Factory Capital's edge will be picking the specific business model where clinical infrastructure converts to durable cash flow. Telehealth-led care, employer benefits and prescription-supply chains all look defensible. Direct-to-consumer supplements probably don't.
The five-to-ten investment portfolio is consistent with a concentration-led platform, not a spray-and-pray thesis fund. At $25M+ deployed across 10 or fewer companies, average cheque size sits between $2.5M and $5M, which is sizeable for a single-thematic platform. That implies strong ownership targets and a hands-on, accelerator-adjacent posture.
Fund Overview
Fund Name: Factory Capital Women's Midlife Health Initiative (linked to the Institute Advancing Women's Health)
Fund Size: $25 million+ planned deployment
Stage: Early to mid-stage
Check Size: Not formally disclosed; implied $2.5M-$5M based on 5-10 portfolio targets
Geography: Global, with Austin-based non-profit anchor and Sydney HQ
Focus: Peri- and post-menopause health, women's midlife clinical infrastructure and commercial businesses
Anchor Institution: Institute Advancing Women's Health (InAWH)
Why This Fund Matters
Women's midlife health has been the most loudly under-invested vertical in healthcare for a decade. Menopause affects roughly half the human population, lasts on average seven to ten years, and intersects with cardiovascular disease, osteoporosis, cognitive function and mental health, yet the venture capital flowing into the category is a rounding error against the size of the addressable problem. Multiple market estimates put the global opportunity between $360 billion and $490 billion. Factory Capital is using the upper end of that range as its anchor.
The reason capital hasn't shown up is not that founders are absent. It is that the category is so fragmented across clinical pathways, payer architectures and consumer routes-to-market that institutional LPs struggle to underwrite a thematic fund. Factory Capital's bet is that the way to unlock the category is to build its plumbing first. The Institute Advancing Women's Health is being structured to convene clinicians, researchers and regulators around treatment protocols and care pathways that, once in place, make the surrounding businesses easier to evaluate, fund and scale.
There is precedent for this approach. The Susan G. Komen Foundation effectively did this for breast cancer in the 1990s and 2000s, building advocacy, screening and clinical-trial infrastructure that subsequently created the conditions for an entire generation of oncology biotech to raise capital and exit. Factory Capital appears to be replicating that playbook for midlife women's health, with a venture-grade commercial layer attached.
The risk in this model is timing. Infrastructure-first plays are deeply contrarian and can take 5-10 years to show commercial traction. LPs accustomed to typical VC vintage curves will need to underwrite a longer J-curve than usual. Factory Capital appears to be funding the initial outlay from its own balance sheet rather than running a conventional LP-funded vehicle, which would explain the platform-style framing.
The Team
Anna Samuelsson, Partner and Managing Director, Factory Capital. Twenty-plus years across investment banking, strategy and operations, including time at Goldman Sachs. Samuelsson sits on the InAWH board of directors and is the public face of Factory Capital's women's midlife health initiative. Her decision to anchor the strategy came in part from her own experience navigating perimenopausal symptoms while being told she was too young for treatment, an insight she has turned into the firm's structural thesis.
Paula Schneider, CEO, Institute Advancing Women's Health. Named to lead InAWH at launch. Schneider's background in women's health advocacy and operational turnaround gives the non-profit a credible chief executive from day one, and signals that Factory Capital is investing in real institution-building rather than a marketing wrapper.
Factory Capital platform. The firm operates HEAL, a private equity platform focused on early-to-mid-stage investments across health, education and related lifestyle sectors, alongside other dedicated vehicles. The midlife women's health initiative sits within Factory Capital's broader investment platform and benefits from 15+ years of category-building experience.
Early Portfolio
The five-to-ten target portfolio is still being assembled. Factory Capital has not yet disclosed individual investments under the women's midlife health initiative. We expect the first announced commitments to land within the next 12 months, with telehealth-led menopause care, employer benefits platforms and clinical-grade supplement supply chains as the most likely initial bets.
What This Means for Founders
If you are building in peri- or post-menopause care, hormone therapy supply chains, employer benefits, midlife mental health, sleep, or related verticals, Factory Capital is going to be one of the most strategic capital sources in the world for you over the next 24 months. The platform comes with non-profit infrastructure access, clinical advisory bandwidth, and a partner who has personally underwritten the thesis with her own time and money.
What the platform will not be a fit for: pure consumer DTC supplement brands without a clinical or care-pathway angle, fertility-focused businesses (an adjacent but distinct market), or hardware-heavy diagnostics outside the immediate menopause-care workflow. Founders should expect a high-touch, opinionated partner that will want to integrate portfolio companies with InAWH's clinical infrastructure where it makes sense.
Fund Momentum Take
This is one of the most structurally interesting moves we have seen in women's health VC. Most thematic women's health funds we have evaluated this cycle have been either too generalist (covering everything from period care to fertility to oncology) or too clinical (oncology-style biotech books that happen to focus on women). Factory Capital is going narrow on midlife and wide on business-model architecture, which is the right combination if you believe the bottleneck is category infrastructure rather than founder supply.
The risk we'd flag for LPs and co-investors is the unusual structure. Factory Capital is not running this as a conventional 10-year LP-funded VC vehicle, at least not from what has been publicly disclosed. That gives the platform more strategic patience but makes return measurement less standardised. Anyone evaluating this on a traditional IRR basis will struggle. Anyone evaluating it as a category-creation platform with an embedded venture book has the right mental model.
Our higher-conviction take: by 2028 there will be five-to-eight institutionally-backed women's midlife health platforms globally. Factory Capital is one of the first to set up the right structure to compound advantage. We expect a meaningful imitator wave within 12 months, particularly from US strategic healthcare investors who have been waiting for the category to look investable.
Frequently Asked Questions
How much capital is Factory Capital deploying?
Factory Capital has publicly committed to investing upwards of $25 million in the midlife women's health initiative, supporting both the Institute Advancing Women's Health non-profit and five to ten commercial businesses.
Who leads the Factory Capital initiative?
Partner and Managing Director Anna Samuelsson leads the firm's women's midlife health strategy. Paula Schneider has been named CEO of the linked Institute Advancing Women's Health (InAWH).
What is the Institute Advancing Women's Health (InAWH)?
InAWH is a new Austin-based global non-profit launched alongside Factory Capital's strategy. It exists to build clinical infrastructure (protocols, care pathways, clinician training) for women's midlife health.
What does Factory Capital invest in?
Factory Capital is a Sydney-based investment platform with a 15-year track record across health, education and related sectors. It also operates HEAL, a private equity platform focused on early-to-mid-stage healthcare and lifestyle investments.
Is this a venture fund or a private equity vehicle?
The midlife women's health strategy is structured as a platform investment with a venture book, not a conventional VC fund. Factory Capital is funding the initial outlay rather than running an LP-syndicated fundraise.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.